UY26616A1 - SPECIFIC ANTIBODIES OF FAP- ALPHA HUMANS - Google Patents

SPECIFIC ANTIBODIES OF FAP- ALPHA HUMANS

Info

Publication number
UY26616A1
UY26616A1 UY26616A UY26616A UY26616A1 UY 26616 A1 UY26616 A1 UY 26616A1 UY 26616 A UY26616 A UY 26616A UY 26616 A UY26616 A UY 26616A UY 26616 A1 UY26616 A1 UY 26616A1
Authority
UY
Uruguay
Prior art keywords
alpha
fap
humans
specific antibodies
antibodies
Prior art date
Application number
UY26616A
Other languages
Spanish (es)
Inventor
John Park
Dr Pilar Garin-Chesa
Dr Klaus Pfizenmaier
Dr Dieter Moosmayer
Michael Mersmann
Alexej Schmidt
Original Assignee
Boheringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boheringer Ingelheim Pharma Kg filed Critical Boheringer Ingelheim Pharma Kg
Publication of UY26616A1 publication Critical patent/UY26616A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a proteínas de anticuerpos que se unen específicamente a proteínas activadora de fibroblastos alfa (FAP-alfa. La invención se refiere, además, al uso de dichos anticuerpos para fines de diagnóstico y terapéuticos, así como a procedimientos para preparar dichos anticuerpos.The invention relates to antibody proteins that specifically bind to alpha fibroblast activating proteins (FAP-alpha. The invention further relates to the use of such antibodies for diagnostic and therapeutic purposes, as well as to methods for preparing said antibodies .

UY26616A 2000-03-17 2001-03-14 SPECIFIC ANTIBODIES OF FAP- ALPHA HUMANS UY26616A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10013286A DE10013286A1 (en) 2000-03-17 2000-03-17 New human humanized antibody that specifically binds to fibroblasts activating protein alpha, useful for treating cancer or tumor, and for imaging tumors associated with activated stromal fibroblasts, e.g. lung or breast cancer

Publications (1)

Publication Number Publication Date
UY26616A1 true UY26616A1 (en) 2001-10-25

Family

ID=7635287

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26616A UY26616A1 (en) 2000-03-17 2001-03-14 SPECIFIC ANTIBODIES OF FAP- ALPHA HUMANS

Country Status (3)

Country Link
AR (1) AR028262A1 (en)
DE (1) DE10013286A1 (en)
UY (1) UY26616A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014167083A1 (en) 2013-04-12 2014-10-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
WO2023125796A1 (en) * 2021-12-30 2023-07-06 Concept To Medicine Biotech Co., Ltd. Human antibodies against fap-alpha

Also Published As

Publication number Publication date
DE10013286A1 (en) 2001-09-20
AR028262A1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
CR8231A (en) ANTIBODIES RG1 AND USE OF THE SAME
CY1119291T1 (en) LITTLE ANTIBODIES AND USES FOR THEM
CY1118880T1 (en) HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND USES
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
CY1118443T1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
EA201100694A1 (en) ANTIBODY TO CD38 PERSON AND ITS APPLICATION
CR10878A (en) ANTIBODIES FOR CD40 (EXP. 7343 DIVISIONAL)
CO6351800A2 (en) ANTI-BODY -17A / IL -17F CROSSED REACTIVITY AND METHODS OF USE OF THE SAME
CO6531481A2 (en) LINK PROTEINS TO THE ANTIGEN IL-23 HUMANS
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
NO20083895L (en) Anti-IGF-1R human monoclonal antibody formulation
NO20041917D0 (en) Specific agents that bind human angiopoietin-2
DE50114428D1 (en) NEW USE OF SHORT-CHAIN CARBOXYLIC ACIDS
ATE513563T1 (en) THERAPEUTIC AND TOLERANCE-INDUCING ANTIBODIES
BR0314814A (en) Optimized variants of fc and methods for their generation
ATE476992T1 (en) NEUTRALIZABLE EPITOPE OF HGF AND NEUTRALIZING ANTIBODIES BINDING TO IT
DE60226486D1 (en) SELF-ARRANGING MOLECULES
EA200801174A1 (en) GLP-2 MIMETIC ANTIBODIES, POLYPEPTIDES, COMPOSITIONS, METHODS AND APPLICATIONS
CL2008001258A1 (en) Vaccine kit comprising at least nine conjugates of saccharides of hb or hib antigens, where at least 2-7 are with the crm transporter protein, said kit being suitable for use in their primary immunization schedule; combination vaccine suitable for primary immunization.
DE60321041D1 (en) ANTIBODY TO CANCERANT TMEFF2 AND ITS APPLICATIONS
DE50111331D1 (en) NEW USE OF PROTEIN HYDROLYSATES
BR0116686A (en) Silenced anti-cd28 Antibodies and usage
AR029624A1 (en) ANTIBODIES OR FRAGMENTS OF RECOMBINANT ANTI-IDIOTIPIC ANTIBODIES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
BR0314716A (en) Lfa-1 alpha subunit antibodies and methods of use
ATE552266T1 (en) MODIFIED HIV-1 ENVELOPE PROTEINS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140908